Bast Biotechnology has developed innovative technology to fight fibrotic disease. The initial indication will target non-alcoholic fibrotic liver disease (NAFLD) and non-alcoholic steatosis hepatitis (NASH).
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
